These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1768762)

  • 1. Fibrinogen Kiel: a congenital dysfibrinogenaemia with (A alpha-16 Arg----His) substitution characterized by HPLC without prior isolation of fibrinogen.
    Seydewitz HH; Gram J; Bruhn HD; Witt I
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):501-6. PubMed ID: 1768762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
    Furlan M; Leupin L; Biasiutti FD; Lämmle B
    Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogens Bern IV, Bern V and Milano XI: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain.
    Stucki B; Zenhäusern R; Biedermann B; Baudo F; Redaelli R; Lämmle B; Furlan M
    Blood Coagul Fibrinolysis; 1999 Mar; 10(2):93-9. PubMed ID: 10192658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen Geneva, a new case of A alpha 16 Arg----Cys dysfibrinogenaemia.
    Furlan M; Bögli C; Hofer A; Bouvier CA; de Moerloose P
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):139-43. PubMed ID: 2130925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
    Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
    Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen New Britain: characterization of an A alpha Arg 16-->His variant human fibrinogen.
    Webb CD; Hantgan RR; Byeff PD; Owen J
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):233-8. PubMed ID: 8054455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary dysfibrinogenaemia (fibrinogen Jena)--report of a family study.
    Maak B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):519-22. PubMed ID: 2465965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrinogen Bern II: hereditary fibrinogen variant with amino acid substitution of arginine replaced by histidine in position 16 of the A alpha chain].
    Rupp C; Sievi R; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1983 Oct; 113(40):1460-2. PubMed ID: 6648427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
    Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
    Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine leads to histidine substitution.
    Southan C; Kehl M; Henschen A; Lane DA
    Br J Haematol; 1983 May; 54(1):143-51. PubMed ID: 6849832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
    Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
    Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Kanazawa: a congenital dysfibrinogenaemia with delayed polymerization having a replacement of proline-18 by leucine in the A alpha-chain.
    Uotani C; Miyata T; Kumabashiri I; Asakura H; Saito M; Matsuda T; Kajiyama S; Iwanaga S
    Blood Coagul Fibrinolysis; 1991 Jun; 2(3):413-7. PubMed ID: 1932527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
    Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
    Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
    Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
    Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
    Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
    Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): fibrinogens Bergamo II, Essen and Perugia.
    Reber P; Furlan M; Henschen A; Kaudewitz H; Barbui T; Hilgard P; Nenci GG; Berrettini M; Beck EA
    Thromb Haemost; 1986 Dec; 56(3):401-6. PubMed ID: 3563970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
    Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
    Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
    Siebenlist KR; Prchal JT; Mosesson MW
    Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (A alpha 20 Val --> Asp).
    Brennan SO; Hammonds B; George PM
    J Clin Invest; 1995 Dec; 96(6):2854-8. PubMed ID: 8675656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.